Chronic Myeloid Leukemia Face-Off: Memorial Sloan Kettering vs Dana-Farber

Steven Frommeyer introduces the two teams of competing physicians participating in Cancer Network® Face-off.

Michael Mauro, MD, presents data on a phase 2 ponatinib dose-ranging study in chronic-phase CML.

Dr Michael Mauro continues his presentation with a look at an analysis of the arterial occlusive events in the PACE trial in CML.

The Dana-Farber team puts Memorial Sloan Kettering to the test and questions the panel on the presented abstracts.

Daniel DeAngelo, MD, PhD, presents data from a phase 3 study comparing asciminib and bosutinib after treatment with 2 or more prior TKIs in CML.

Dr DeAngelo shares data on the use of ponatinib for CML treatment after failure of second-generation TKIs.

The Memorial Sloan Kettering team gets their chance to question the Dana-Farber team on the datasets they presented.

Two teams from leading institutions go head-to-head to debate the latest datasets and advances in chronic myeloid leukemia (CML).